Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Recruiting 10Active not recruiting 6Completed 3Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 42OTHER 24NETWORK 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

Radiotherapy 214Cisplatin 180Cyclophosphamide 169Doxorubicin 138Vincristine 127Paclitaxel 125Filgrastim 121Etoposide 104Carboplatin 100Methotrexate 83Gemcitabine 82Docetaxel 78Cytarabine 78Gene Expression Profiling 74Fluorouracil 74Prednisone 71Granulocyte Colony-Stimulating Factor 66Dexamethasone 66Leucovorin 62Polymerase Chain Reaction 47Immunohistochemistry 46Microarray Analysis 40Daunorubicin 38Irinotecan 37Ifosfamide 37Temozolomide 35Cetuximab 33Amplified Fragment Length Polymorphism Analysis 33Peripheral Blood Stem Cell Transplantation 32Mercaptopurine 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × NETWORK × daratumumab × Clear all
NCT03180736 2025-12-19

EMN14

European Myeloma Network B.V.

Phase 3 Completed
304 enrolled 19 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT02541383 2025-04-13

Cassiopeia

Intergroupe Francophone du Myelome

Phase 3 Completed
1,085 enrolled 22 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT03732703 2025-02-14

MyDRUG

Multiple Myeloma Research Consortium

Phase 1/2 Completed
103 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡